Article Text

Download PDFPDF
Delirious mania in a patient with COVID-19 pneumonia
  1. Peter M Haddad1,
  2. Majid Alabdulla2,
  3. Javed Latoo1 and
  4. Yousaf Iqbal1
  1. 1Psychiatry, Hamad Medical Corporation, Doha, Qatar
  2. 2Consultation Liaison Psychiatry, Hamad Medical Corporation, Doha, Qatar
  1. Correspondence to Professor Peter M Haddad; Phaddad{at}hamad.qa

Abstract

Delirious mania (the coexistence of delirium and mania) is described in the literature but not recognised in standard nosologies. We report a woman in her late 30s, with no psychiatric history, who presented with concurrent symptoms of mania and delirium. She was diagnosed with COVID-19 pneumonia (positive reverse transcription-PCR test). There was no history of substance misuse or concurrent medical illness. CT head scan was normal as were blood investigations, other than elevated inflammatory markers. She received standard treatment for COVID-19 pneumonia and lorazepam and quetiapine to treat her neuropsychiatric symptoms. She made a full recovery after 9 days. She was apyrexial with normal oxygen saturation throughout her illness. The case shows that severe neuropsychiatric symptoms can complicate otherwise mild COVID-19 pneumonia with neuroinflammation being a possible mechanism. A diagnosis of delirious mania appears to better capture the complexity of the presentation than a diagnosis of mania or delirium alone.

  • COVID-19
  • delirium
  • bipolar I disorder
  • psychiatry (drugs and medicines)

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors PMH and YI conceptualised the paper and wrote the initial draft. All authors (PMH, MA, JL, YI) contributed to reviewing the literature, interpreting the data and revising the manuscript and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests PMH reports personal fees from Janssen, NewBridge Pharmaceuticals and Otsuka, outside the submitted work.

  • Provenance and peer review Not commissioned; externally peer reviewed.